Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.95|
|52 Week High||AU$0.48|
|52 Week Low||AU$1.48|
|1 Month Change||-10.80%|
|3 Month Change||2.70%|
|1 Year Change||88.12%|
|3 Year Change||304.26%|
|5 Year Change||304.26%|
|Change since IPO||322.22%|
Recent News & Updates
We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|PIQ||AU Life Sciences||AU Market|
Return vs Industry: PIQ exceeded the Australian Life Sciences industry which returned 23.9% over the past year.
Return vs Market: PIQ exceeded the Australian Market which returned 24.4% over the past year.
Stable Share Price: PIQ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PIQ's weekly volatility (8%) has been stable over the past year.
About the Company
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy.
Proteomics International Laboratories Fundamentals Summary
|PIQ fundamental statistics|
Is PIQ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PIQ income statement (TTM)|
|Cost of Revenue||AU$813.74k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.027|
|Net Profit Margin||-104.53%|
How did PIQ perform over the long term?See historical performance and comparison
Is Proteomics International Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PIQ is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.
PE vs Market: PIQ is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PIQ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PIQ is overvalued based on its PB Ratio (13.1x) compared to the AU Life Sciences industry average (5.2x).
How is Proteomics International Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Proteomics International Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Proteomics International Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PIQ is currently unprofitable.
Growing Profit Margin: PIQ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PIQ is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare PIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PIQ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (60%).
Return on Equity
High ROE: PIQ has a negative Return on Equity (-37.58%), as it is currently unprofitable.
How is Proteomics International Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: PIQ's short term assets (A$7.3M) exceed its short term liabilities (A$779.0K).
Long Term Liabilities: PIQ's short term assets (A$7.3M) exceed its long term liabilities (A$211.2K).
Debt to Equity History and Analysis
Debt Level: PIQ is debt free.
Reducing Debt: PIQ has no debt compared to 5 years ago when its debt to equity ratio was 55%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PIQ has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PIQ has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 8.8% each year.
What is Proteomics International Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PIQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PIQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PIQ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PIQ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PIQ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Richard John Lipscombe, Ph D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD215.94K) is about average for companies of similar size in the Australian market ($USD284.01K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
Experienced Management: PIQ's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: PIQ's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.9%.
Proteomics International Laboratories Limited's employee growth, exchange listings and data sources
- Name: Proteomics International Laboratories Limited
- Ticker: PIQ
- Exchange: ASX
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$99.993m
- Shares outstanding: 105.26m
- Website: https://www.proteomics.com.au
- Proteomics International Laboratories Limited
- QEII Medical Centre
- QQ Block
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 08:06|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.